amylase 39150 UNT / lipase 10440 UNT / protease 39150 UNT Oral Tablet [Viokace]
amylase
RxCUI: 1247388
What the CMS Formulary Data Shows for amylase 39150 UNT / lipase 10440 UNT / protease 39150 UNT Oral Tablet [Viokace]
Per the CMS 2026 Part D formulary file, amylase 39150 UNT / lipase 10440 UNT / protease 39150 UNT Oral Tablet [Viokace] (RxNorm concept RXCUI 1247388, generic name amylase) appears on 5 distinct formulary files spanning 7 Medicare Part D plan offerings - 0.1% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 4, with a cross-plan average of Tier 2.4.
Real-world access to amylase 39150 UNT / lipase 10440 UNT / protease 39150 UNT Oral Tablet [Viokace] depends on utilization management as much as tier placement: 20% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 637 Part D beneficiaries filled amylase 39150 UNT / lipase 10440 UNT / protease 39150 UNT Oral Tablet [Viokace] in 2023, with total plan-and-beneficiary spending of $2,582,612 and an average per-beneficiary annual cost of $4,054.34. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry amylase 39150 UNT / lipase 10440 UNT / protease 39150 UNT Oral Tablet [Viokace] today.
Coverage Details
- Formularies covering
- 5
- Plans covering
- 7
- Coverage rate
- 0.1%
- Tier range
- Tier 1 – Tier 4
- Average tier
- Tier 2, Generic
Restrictions
- Prior authorization required
- 20% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 0% of formularies
2023 Medicare Spending
- Beneficiaries
- 637
- Total spending
- $2,582,612
- Avg per beneficiary
- $4,054.34
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering amylase 39150 UNT / lipase 10440 UNT / protease 39150 UNT Oral Tablet [Viokace]
7 Medicare Advantage plans with Part D drug coverage include this drug.
| Plan | Insurer | Tier | PA | Premium | States |
|---|---|---|---|---|---|
| Mass General Brigham SCO (HMO D-SNP) | MASS GENERAL BRIGHAM HEALTH PLAN, INC | T1 | No | $0 | MA |
| Mass General Brigham One Care (HMO D-SNP) | MASS GENERAL BRIGHAM HEALTH PLAN, INC | T1 | No | $0 | MA |
| CalOptima Health OneCare Complete (HMO D-SNP) | ORANGE COUNTY HEALTH AUTHORITY | T2 | Yes | $0 | CA |
| Mass General Brigham Advantage (PPO) | Mass General Brigham Health Plan, Inc. | T4 | No | $0 | MA |
| Mass General Brigham Advantage Secure (HMO-POS) | Mass General Brigham Health Plan, Inc. | T4 | No | $62.00 | MA |
| Mass General Brigham Advantage Premier (PPO) | Mass General Brigham Health Plan, Inc. | T4 | No | $79.70 | MA |
| Mass General Brigham Advantage Signature (PPO) | Mass General Brigham Health Plan, Inc. | T4 | No | $147.20 | MA |
Frequently Asked Questions
Is amylase 39150 UNT / lipase 10440 UNT / protease 39150 UNT Oral Tablet [Viokace] covered by Medicare Part D?
Yes, amylase 39150 UNT / lipase 10440 UNT / protease 39150 UNT Oral Tablet [Viokace] is covered by 7 Medicare Part D plans (0.1% of all Part D formularies).
What tier is amylase 39150 UNT / lipase 10440 UNT / protease 39150 UNT Oral Tablet [Viokace] on Medicare Part D plans?
amylase 39150 UNT / lipase 10440 UNT / protease 39150 UNT Oral Tablet [Viokace] averages Tier 2.4 across Part D plans, ranging from Tier 1 to Tier 4.
Does amylase 39150 UNT / lipase 10440 UNT / protease 39150 UNT Oral Tablet [Viokace] require prior authorization?
20% of Part D formularies require prior authorization for amylase 39150 UNT / lipase 10440 UNT / protease 39150 UNT Oral Tablet [Viokace]. Step therapy: 0%. Quantity limits: 0%.
How much does Medicare spend on amylase 39150 UNT / lipase 10440 UNT / protease 39150 UNT Oral Tablet [Viokace]?
In 2023, total Medicare Part D spending on amylase 39150 UNT / lipase 10440 UNT / protease 39150 UNT Oral Tablet [Viokace] was $2,582,612, covering 637 beneficiaries. The average spend per beneficiary was $4,054.34.
Read our methodology - how this data is sourced, computed, and verified.